Columbia University

Tonix Pharma Holdings Limited

Other

Tonix Pharmaceuticals Holding Corp.

Follica, Inc.

City University of New York

Vela Pharmaceuticals, Inc.

Tonix Pharmaceuticals Inc.

Tonix Pharma Holdings Limited (bermuda)

Krele Pharmaceuticals, Inc.

Seth Lederman

Leonard Chess

Michael J Yellin

Shikha P Barman

Scott C Kellogg

Giorgio Reiner

Marino Nebuloni

Stephen M Prouty

Darryl C Rideout

Alan D Schinazi

William D Ju

Eric Schweiger

Mary Osbakken

Winfried Van Eyndhoven

Greg Sullivan

Herb Harris

Herbert W Harris

Andrew Mamoru Kawasaki

David Evans

David Baltimore

Cy Aaron Stein

Leland J Gershell

Genhong Cheng

Iredell W Iglehart, Iii

Ryan Noyce

Aileen Anne Cleary

Darryl Rideout

Zheng-Sheng Ye

Gregory Sullivan

Bruce Daugherty

Herbert Harris

Harry Brittain

The invention relates to methods of treating baldness, treating alopecia, promoting hair growth, and/or promoting hair follicle development and/or activation or stimulation on an area of the skin of a subject (for example, a human) by subjecting said area of the skin to integumental perturbation. Integumental perturbation can be used in combination with other treatments for promoting hair growth. The invention provides devices for integumental perturbation for promoting hair growth, and provides pharmaceutical compositions for use in combination with integumental perturbation for promoting hair growth.

Methods for treating baldness and promoting hair growth

The present invention relates to cyclobenzaprine analogs and amitriptyline analogs, including deuterated forms useful for treatment or prevention of symptoms associated with post-traumatic stress disorder.

Analogs of cyclobenzaprine and amitryptilene

The present invention relates to methods for the treatment or prevention of depression, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising cyclobenzaprine, alone, or in combination with an antidepressant drug.

Methods and compositions for treating depression using cyclobenzaprine

Compositions comprising cyclobenzaprine, and methods for the treatment or prevention of agitation, psychosis and/or cognitive decline and associated symptoms thereof in dementia and other neurodegenerative conditions.

Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions

Analogs of cyclobenzaprine and amitriptyline

The invention relates, in general, to synthetic chimeric poxviruses, compositions comprising such viruses, and the development and use of systems and methods for producing such synthetic chimeric poxviruses. The synthetic chimeric poxviruses are well suited for live virus vaccines and pharmaceutical formulations.

Synthetic chimeric poxviruses

The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol.

Eutectic formulations of cyclobenzaprine hydrochloride

The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine. The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment.

Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine

The present invention relates to methods for the treatment or prevention of symptoms associated with post-traumatic stress disorder, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising a very low dose of cyclobenzaprine, alone, or in combination with an alpha-1-adrenergic receptor antagonist, a beta-adrenergic antagonist, an anticonvulsant, a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor.

Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine

The invention relates to a purified Isometheptene compound comprising the structure according to Formula (I), or a hydrochloride, or a pharmaceutically acceptable addition salt thereof. In particular, the disclosure relates to the synthesis, purification and characterization of an Isometheptene isomer mucate crystal 2, wherein the Isometheptene isomer 2 is stereochemically characterized as (R)-enantiomer, respectively. The Isometheptene (R)-enantiomer activity indicates a selective centrally acting selective ligand for Imidazoline subtype 1 (I1) receptor sites; and more specifically, the disclosure provides an antihypertensive composition for treatment of migraine and other neurovascular or neurogenic pain from abdominal distress. (R)-Isometheptene enantiomer or isomer 2 may be an anti-hypertensive agent with lower side effects than the racemate form. Therefore (R)-Isometheptene is believed to be effective against episodic tension-type headaches (ETTH). The (R)-Isometheptene enantiomer or isomer 2 is believed to effectively lower blood pressure, used alone or together with other headache ameliorating drugs. Methods of synthesis and treatment are described. Regarding (R)-Isometheptene crystals data of X-ray crystallography are presented.

Isometheptene isomer

Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.

Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism

Growing community of inventors

New York, NY, United States of America

Seth Lederman